Cargando…
Natural Killer Cell-Based Immunotherapy against Glioblastoma
Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916747/ https://www.ncbi.nlm.nih.gov/pubmed/36768432 http://dx.doi.org/10.3390/ijms24032111 |
_version_ | 1784886200824233984 |
---|---|
author | Morimoto, Takayuki Nakazawa, Tsutomu Maeoka, Ryosuke Nakagawa, Ichiro Tsujimura, Takahiro Matsuda, Ryosuke |
author_facet | Morimoto, Takayuki Nakazawa, Tsutomu Maeoka, Ryosuke Nakagawa, Ichiro Tsujimura, Takahiro Matsuda, Ryosuke |
author_sort | Morimoto, Takayuki |
collection | PubMed |
description | Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS is poor. Considering the poor prognosis, novel treatment strategies are needed, such as immunotherapies, which include chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and oncolytic virus therapy. However, these therapies have not achieved satisfactory outcomes. One reason for this is that these therapies are mainly based on activating T cells and controlling GBM progression. Natural killer (NK) cell-based immunotherapy involves the new feature of recognizing GBM via differing mechanisms from that of T cell-based immunotherapy. In this review, we focused on NK cell-based immunotherapy as a novel GBM treatment strategy. |
format | Online Article Text |
id | pubmed-9916747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99167472023-02-11 Natural Killer Cell-Based Immunotherapy against Glioblastoma Morimoto, Takayuki Nakazawa, Tsutomu Maeoka, Ryosuke Nakagawa, Ichiro Tsujimura, Takahiro Matsuda, Ryosuke Int J Mol Sci Review Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults. Despite multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, the median overall survival (OS) after diagnosis is approximately 2 years and the 5-year OS is poor. Considering the poor prognosis, novel treatment strategies are needed, such as immunotherapies, which include chimeric antigen receptor T-cell therapy, immune checkpoint inhibitors, vaccine therapy, and oncolytic virus therapy. However, these therapies have not achieved satisfactory outcomes. One reason for this is that these therapies are mainly based on activating T cells and controlling GBM progression. Natural killer (NK) cell-based immunotherapy involves the new feature of recognizing GBM via differing mechanisms from that of T cell-based immunotherapy. In this review, we focused on NK cell-based immunotherapy as a novel GBM treatment strategy. MDPI 2023-01-20 /pmc/articles/PMC9916747/ /pubmed/36768432 http://dx.doi.org/10.3390/ijms24032111 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Morimoto, Takayuki Nakazawa, Tsutomu Maeoka, Ryosuke Nakagawa, Ichiro Tsujimura, Takahiro Matsuda, Ryosuke Natural Killer Cell-Based Immunotherapy against Glioblastoma |
title | Natural Killer Cell-Based Immunotherapy against Glioblastoma |
title_full | Natural Killer Cell-Based Immunotherapy against Glioblastoma |
title_fullStr | Natural Killer Cell-Based Immunotherapy against Glioblastoma |
title_full_unstemmed | Natural Killer Cell-Based Immunotherapy against Glioblastoma |
title_short | Natural Killer Cell-Based Immunotherapy against Glioblastoma |
title_sort | natural killer cell-based immunotherapy against glioblastoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916747/ https://www.ncbi.nlm.nih.gov/pubmed/36768432 http://dx.doi.org/10.3390/ijms24032111 |
work_keys_str_mv | AT morimototakayuki naturalkillercellbasedimmunotherapyagainstglioblastoma AT nakazawatsutomu naturalkillercellbasedimmunotherapyagainstglioblastoma AT maeokaryosuke naturalkillercellbasedimmunotherapyagainstglioblastoma AT nakagawaichiro naturalkillercellbasedimmunotherapyagainstglioblastoma AT tsujimuratakahiro naturalkillercellbasedimmunotherapyagainstglioblastoma AT matsudaryosuke naturalkillercellbasedimmunotherapyagainstglioblastoma |